Article

AIM: To determine whether intrathecal baclofen (ITB) therapy improves performance
and performance satisfaction in goal areas identified by patients' parents.
METHOD: This study formed part of an ongoing multicentre national audit involving
six paediatric ITB pump implant centres across Australia.
The Canadian
Occupational Performance Measure was the primary outcome measure utilized at
baseline, 6 months, and 12 months after pump implants in paediatric patients
receiving ITB therapy for the first time between 31st December 2009 and 31st
December 2014. RESULTS: Twenty-five children had goals identified (mean age 11y
1mo), 19 had a diagnosis of cerebral palsy and 22 were at Gross Motor Function
Classification System level IV, V, or equivalent. Strong evidence for an
improvement in goal performance (2.33, 95% CI 1.70, 2.96, p<0.001) and
performance satisfaction scores (3.08, 95% CI 2.28, 3.88, p<0.001) were
demonstrated at 6 months, compared to baseline. The differences were clinically
significant and were sustained to 12 months. INTERPRETATION: ITB therapy in
paediatric patients with hypertonia results in clinically significant
improvements in average performance and performance satisfaction scores. The most commonly identified goals of parents of children
treated with intrathecal (ITB) therapy were: improving ease of dressing,
positioning, and transfers. ITB therapy is effective in improving performance and
performance satisfaction in children with hypertonia. Score improvements are
mainly evident within the first 6 months of therapy.
CI - (c) 2018 Mac Keith Press.
- Spasticité

Langue : ANGLAIS